Patents by Inventor Geraldine C. B. Harriman

Geraldine C. B. Harriman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemokine receptor antagonists and methods of use
    Patent number: 9663537
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 30, 2017
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • CCR1 antagonists and methods of use thereof
    Patent number: 9334283
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: May 10, 2016
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • CCR9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20160068479
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: April 15, 2015
    Publication date: March 10, 2016
    Inventors: Paul E. Fleming, Geraldine C.B. Harriman, Zhan Shi, B. Shaowu Chen
  • CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20160031908
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Application
    Filed: March 10, 2015
    Publication date: February 4, 2016
    Inventors: Jay R. LULY, Yoshisuke NAKASATO, Etsuo OHSHIMA, Geraldine C.B. HARRIMAN, Kenneth G. CARSON, Shomir GHOSH, Amy M. ELDER, Karen M. MATTIA
  • CCR9 inhibitors and methods of use thereof
    Patent number: 9035096
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 19, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • CCR1 ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20150005338
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Application
    Filed: February 4, 2014
    Publication date: January 1, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C.B. Harriman, Shomir Ghosh
  • CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20140371207
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Application
    Filed: December 13, 2013
    Publication date: December 18, 2014
    Applicants: Kyowa Hakko Kirin Co., Ltd., Millennium Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C.B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • CCR9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20140107160
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: October 9, 2013
    Publication date: April 17, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C.B. Harriman, Zhan Shi, B. Shaowu Chen
  • Chemokine receptor antagonists and methods of use thereof
    Patent number: 8653096
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: February 18, 2014
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • CCR9 inhibitors and methods of use thereof
    Patent number: 8569543
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: October 29, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • CCR1 antagonists and methods of use therefor
    Patent number: 8394817
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: March 12, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20120046311
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Application
    Filed: September 26, 2011
    Publication date: February 23, 2012
    Applicant: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • CCR9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20110313000
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: August 30, 2011
    Publication date: December 22, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 8058287
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: November 15, 2011
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • CCR9 inhibitors and methods of use thereof
    Patent number: 8030517
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: October 4, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • CCR1 Antagonists and Methods of Use Therefor
    Publication number: 20110230516
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 22, 2011
    Inventors: Kenneth G. Carson, Geraldine C.B. Harriman, Shomir Ghosh
  • CCR9 inhibitors and methods of use thereof
    Patent number: 7999109
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: August 16, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
  • CCR1 antagonists and methods of use therefor
    Patent number: 7977350
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: July 12, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • Beta-carbolines useful for treating inflammatory disease
    Patent number: 7951801
    Abstract: This invention provides beta-carboline compounds of formula III-A-aa: wherein Q, G, R1, R2, R3, and R6b are as described in the specification. The compounds are useful for treating diseases such as inflammatory diseases and cancer.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: May 31, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Michael E. Hepperle, Julie Fields Liu, Francois Soucy, Prakash Raman, Jeremy D. Little, Paul E. Fleming, Dominic Reynolds, Geraldine C. B. Harriman
  • CCR9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20100324093
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: August 26, 2010
    Publication date: December 23, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen